|
 |
| home > epc > summer 2002 > marketing and providing health information via e-mail - less is more? |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
E-mail communication is now recognised as one of the fastest growing activities around the world. Many pharmaceutical companies, forever pioneering and positive, are currently exploring, evolving, reshaping and developing a variety of ideas on how to better use e-mail internally. Thinking outside their box, a key challenge for pharmaceutical companies over the next five years will be how to design, develop, deliver and maintain efficient, effective and legitimate e-mail links with contacts outside the company.
There are some shimmers of light emerging from the regulatory clouds, as demonstrated by the European Commission's proposals to allow pharmaceutical companies to provide more information to European patients with AIDS, asthma or diabetes in a five-year pilot exercise. According to Erkki Liikanen (Member of the European Commission responsible for Enterprise and Information Society)'s spokesman, while the exercise is supposed to improve the level and quality of information relating to certain drugs and address the imbalance in information for those without access to the Internet rather than those with access, the opportunities presented by e-mail should not be ignored. E-mail can be so effective.
While e-mail customer relation management (e-CRM) has picked up in industries such as banking, insurance, holidays and travel, it is in the realms of health care that e-CRM has truly great potential. This is for two reasons: the growing number of people online, and the growing interest in health care and health information.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
